Volitionrx Ltd. (NYSE:VNRX) is a developer of blood-based diagnostics for cancer that detect the quantity and composition of cell-free nucleosomes (a complex of protein and DNA) present in the blood. The company announced its first commercial product, the NuQ triage colorectal cancer test, will launch in select European countries in early 2017. The product is not a diagnostic test, but is designed to reduce the number of colonoscopies by screening false positives from fecal immunochemical tests (FIT).
Triage test to be marketed for European screening
Of the 28 EU member states, 14 have established colorectal cancer screening programs, most based on FIT testing. However, the number of false positive FITs is substantial and unnecessary colonoscopies are a burden on the medical system. The NuQ triage test will be used after a positive FIT test to rule out unnecessary colonoscopies, up to 25% based on company estimates. The company will be marketing the test directly to these European central health authorities.
To read the entire report Please click on the pdf File Below